Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Solazyme (TVIA) jumped 10% today after the company reported earnings.
So what: Revenue decreased 17% to $11.2 million and the company reported a loss of $0.28 per share, both of which were ahead of estimates. But revenue isn't all that important at this phase, so investors were focused on final terms of a commercial supply deal with Sasol and the prospect of significant revenue from production later this year.
Now what: Solazyme has been getting a lot of hype for years now and it's almost time for rubber to hit the road. The biggest concern for the company is that highly valued products will become less valuable as it floods the market with supply, something we saw in the rare-earth-mineral market last year. I'm just not buying the hype, and though I may miss out on a big opportunity, I'll stay out of Solazyme until I see top- and bottom-line results.
Interested in more info on Solazyme? Add it to your watchlist by clicking here.
